Gilead Sciences, Inc. (GILD) · Oct 29, 2026 · Earnings
Beat — Non-GAAP EPS $2.55 vs ~$2.18 consensus; revenue $8.30B vs ~$7.81B
Gilead’s Q3 earnings beat revenue and adjusted EPS expectations on 18% HIV growth, while acquisition charges pushed full-year EPS guidance lower.
Gilead remains an HIV-led biopharma company, using long-acting lenacapavir to extend its prevention and treatment franchise while building out oncology and inflammation through launches, trials and acquisitions.
The quarter beat the market’s bar by a wide margin. Revenue reached $8.30 billion versus published consensus of roughly $7.81 billion, while non-GAAP diluted EPS was $2.55 versus approximately $2.18 expected. Product sales rose 13%, led by an 18% jump in HIV, with Descovy up 49% and Trodelvy up 42% year over year.
| Q3 2026 | Q3 2025 | Consensus / prior guide | |
|---|---|---|---|
| Total revenue (Financial Highlights) | $8.30B (+6.8%) | $7.77B | ~$7.81B |
| Non-GAAP diluted EPS (Non-GAAP results) | $2.55 (+3.2%) | $2.47 | ~$2.18 |
| HIV sales (Segment results — HIV) | $6.25B (+18%) | $5.28B | |
| Product sales (Guidance) | $31.0B–$31.3B | $30.1B–$30.4B prior | |
| Non-GAAP diluted EPS guide (Guidance) | $(1.20)–$(0.85) | $(0.65)–$(0.30) prior |
The underlying commercial story improved, especially in HIV. Gilead raised full-year product-sales guidance by $900 million at the midpoint, and the increase is not coming from Veklury: ex-Veklury sales guidance also rose by $900 million. HIV prevention is beginning to matter financially, with Yeztugo contributing $305 million in the quarter and total HIV sales reaching $6.25 billion.
The catch is that Gilead is buying this pipeline at a heavy near-term accounting cost. Full-year non-GAAP EPS guidance was cut to a loss of $1.20–$0.85 from a loss of $0.65–$0.30, while the company says approximately $9.88 per share of the 2026 impact comes from acquired in-process R&D charges tied to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions. That makes the EPS guide less useful as a measure of core operating momentum, but it also confirms that the growth strategy is consuming cash: cash and marketable securities fell to $6.4 billion from $10.6 billion at year-end after $11.3 billion of acquisition outflows.
The pipeline news adds strategic support, but not near-term revenue certainty. FDA approval of Bixlenvo strengthens the HIV franchise, while the Phase 2 emvistegrast result clears its primary endpoint and supports a planned Phase 3 start in 2027. These are meaningful additions to the growth story, but the inflammation asset remains investigational and Gilead’s oncology and cell-therapy performance is still uneven. 〔0〕 〔1〕
Bottom line: This was a real operating beat and a stronger-than-expected quarter, powered by HIV and rising base-business sales. The offset is that Gilead is paying for future growth through large acquisition charges and cash outlays, leaving the overall message mixed rather than cleanly positive.
Phase 3 emvistegrast study initiation in 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!